Male Breast Cancer: Developing Drugs for Treatment

On 12 August 2020 the FDA announced the availability of the guidance for industry.

This guidance provides recommendations to sponsors regarding the development and labeling of cancer drugs, including biological products, regulated by CDER and CBER for the treatment of male patients with breast cancer.

Read more online 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /